AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteGDC-0449 (Vismodegib) is a more potent novel and specific synthetic oral hedgehog pathway inhibitor with an IC50 of 3 nM.
More Information Supplier PageGDC-0449 (Vismodegib) is a more potent novel and specific synthetic oral hedgehog pathway inhibitor with an IC50 of 3 nM.
More Information Supplier PageGDC-0449 (Vismodegib) is a more potent novel and specific synthetic oral hedgehog pathway inhibitor with an IC50 of 3 nM.
More Information Supplier PageGDC-0834 is a potent and selective inhibitor of Bruton’s tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis.
More Information Supplier PageGDC-0834 is a potent and selective inhibitor of Bruton’s tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis.
More Information Supplier PageGDC-0834 is a potent and selective inhibitor of Bruton’s tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis.
More Information Supplier PageGDC-0834 is a potent and selective inhibitor of Bruton’s tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis.
More Information Supplier PageGDC-0879 is a specific inhibitor of B-Raf kinase enzyme,targeting B-Raf (V600E) (IC50: 0.13 nM).
More Information Supplier PageGDC-0879 is a specific inhibitor of B-Raf kinase enzyme,targeting B-Raf (V600E) (IC50: 0.13 nM).
More Information Supplier PageGDC-0879 is a specific inhibitor of B-Raf kinase enzyme,targeting B-Raf (V600E) (IC50: 0.13 nM).
More Information Supplier PageGDC-0879 is a specific inhibitor of B-Raf kinase enzyme,targeting B-Raf (V600E) (IC50: 0.13 nM).
More Information Supplier PageGDC-0879 is a specific inhibitor of B-Raf kinase enzyme,targeting B-Raf (V600E) (IC50: 0.13 nM).
More Information Supplier PageGDC-0941 is a potent, selective, orally bioavailable inhibitor of class I PI3 kinase (PI3K) , with IC50 values (nM) of 3, 33, 3, 75, 1230 and 580 for p110 ??, ??, ?? and ?? isoforms, DNA-PK and mTOR respectively.
More Information Supplier PageGDC-0941 is a potent, selective, orally bioavailable inhibitor of class I PI3 kinase (PI3K) , with IC50 values (nM) of 3, 33, 3, 75, 1230 and 580 for p110 ??, ??, ?? and ?? isoforms, DNA-PK and mTOR respectively.
More Information Supplier PageGDC-0941 is a potent, selective, orally bioavailable inhibitor of class I PI3 kinase (PI3K) , with IC50 values (nM) of 3, 33, 3, 75, 1230 and 580 for p110 ??, ??, ?? and ?? isoforms, DNA-PK and mTOR respectively.
More Information Supplier PageGDC-0941 is a potent, selective, orally bioavailable inhibitor of class I PI3 kinase (PI3K) , with IC50 values (nM) of 3, 33, 3, 75, 1230 and 580 for p110 ??, ??, ?? and ?? isoforms, DNA-PK and mTOR respectively.
More Information Supplier PageGDC-0941 is a potent, selective, orally bioavailable inhibitor of class I PI3 kinase (PI3K) , with IC50 values (nM) of 3, 33, 3, 75, 1230 and 580 for p110 ??, ??, ?? and ?? isoforms, DNA-PK and mTOR respectively.
More Information Supplier PageGDC-0973, a selective inhibitor of MEK, also known as mitogen activated protein kinase kinase (MAPKK), is a key component of the RAS/RAF/MEK/ERK pathway, which is frequently activated in human tumors.
More Information Supplier PageGDC-0973, a selective inhibitor of MEK, also known as mitogen activated protein kinase kinase (MAPKK), is a key component of the RAS/RAF/MEK/ERK pathway, which is frequently activated in human tumors.
More Information Supplier PageGDC-0973, a selective inhibitor of MEK, also known as mitogen activated protein kinase kinase (MAPKK), is a key component of the RAS/RAF/MEK/ERK pathway, which is frequently activated in human tumors.
More Information Supplier PageGDC-0980 (RG7422) is a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with in vitro IC50 of 5, 27, 7 and 14 nM for p110 ??, ??, ?? and ?? isoforms, respectively.
More Information Supplier PageGDC-0980 (RG7422) is a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with in vitro IC50 of 5, 27, 7 and 14 nM for p110 ??, ??, ?? and ?? isoforms, respectively.
More Information Supplier PageGDC-0980 (RG7422) is a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with in vitro IC50 of 5, 27, 7 and 14 nM for p110 ??, ??, ?? and ?? isoforms, respectively.
More Information Supplier PageGDC-0980 (RG7422) is a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with in vitro IC50 of 5, 27, 7 and 14 nM for p110 ??, ??, ?? and ?? isoforms, respectively.
More Information Supplier PageGDC-0980 (RG7422) is a selective, potent, orally bioavailable inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) with in vitro IC50 of 5, 27, 7 and 14 nM for p110 ??, ??, ?? and ?? isoforms, respectively.
More Information Supplier PageGDC-0994 is a potent and selective Erk1/2 inhibitor. GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways.
More Information Supplier PageGDC-0994 is a potent and selective Erk1/2 inhibitor. GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways.
More Information Supplier PageGDC-0994 is a potent and selective Erk1/2 inhibitor. GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways.
More Information Supplier PageGDC-0994 is a potent and selective Erk1/2 inhibitor. GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways.
More Information Supplier PageGefarnate is a synthetic isoprenoid that is used to treat chronic gastric and duodenic ulcers.
More Information Supplier PageGefarnate is a synthetic isoprenoid that is used to treat chronic gastric and duodenic ulcers.
More Information Supplier PageGefitinib is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells.
More Information Supplier PageGefitinib is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells.
More Information Supplier PageGefitinib is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells.
More Information Supplier PageGefitinib is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells.
More Information Supplier PageGefitinib hydrochloride is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR.
More Information Supplier PageGefitinib hydrochloride is an EGFR inhibitor, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR.
More Information Supplier PageGeldanamycin binds to the ATP site of Hsp90 (Kd = 1.2 ??M) and inhibits its chaperone activity.
More Information Supplier PageGeldanamycin binds to the ATP site of Hsp90 (Kd = 1.2 ??M) and inhibits its chaperone activity.
More Information Supplier PageGeldanamycin binds to the ATP site of Hsp90 (Kd = 1.2 ??M) and inhibits its chaperone activity.
More Information Supplier PageGeldanamycin binds to the ATP site of Hsp90 (Kd = 1.2 ??M) and inhibits its chaperone activity.
More Information Supplier PageGeldanamycin binds to the ATP site of Hsp90 (Kd = 1.2 ??M) and inhibits its chaperone activity.
More Information Supplier PageGemcitabine elaidate is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity.
More Information Supplier PageGemcitabine elaidate is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity.
More Information Supplier PageGemcitabine elaidate is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity.
More Information Supplier PageGemcitabine elaidate is a lipophilic, unsaturated fatty acid ester derivative of gemcitabine (dFdC), an antimetabolite deoxynucleoside analogue, with potential antineoplastic activity.
More Information Supplier PageGemcitabine (Gemzar) is a newer chemotherapy drug acting by replacing one of the building blocks of nucleic acids during DNA replication in cancer cells, preventing tumor growth.
More Information Supplier PageGemcitabine (Gemzar) is a newer chemotherapy drug acting by replacing one of the building blocks of nucleic acids during DNA replication in cancer cells, preventing tumor growth.
More Information Supplier PageGemcitabine (Gemzar) is a newer chemotherapy drug acting by replacing one of the building blocks of nucleic acids during DNA replication in cancer cells, preventing tumor growth.
More Information Supplier PageGemcitabine (Gemzar) is a newer chemotherapy drug acting by replacing one of the building blocks of nucleic acids during DNA replication in cancer cells, preventing tumor growth.
More Information Supplier Page
